Inari Medical Appoints Robert Warner to Board of Directors

Rhea-AI Summary

Inari Medical, Inc. (NASDAQ: NARI) announced the appointment of Robert Warner to its board of directors as a member of the Audit Committee. Warner brings extensive experience, having served in various executive roles at Alcon, including President of the U.S. and Canada. His leadership is anticipated to add significant value as Inari advances its mission to treat patients with venous diseases. The company specializes in minimally-invasive devices for treating deep vein thrombosis and pulmonary embolism, which are FDA-cleared and CE Mark approved.

Positive

• Robert Warner's extensive executive experience in the medical field is expected to provide valuable insights.
• Appointment strengthens the board's expertise as Inari pursues growth in the medical device sector.

Negative

• No immediate concerns identified.

IRVINE, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced the appointment of Mr. Robert Warner to its board of directors. Mr. Warner will serve as a member of the Audit Committee of the board.

“We are pleased to welcome Robert as a new independent director to our board. Mr. Warner’s decades of executive operating experience, including internationally, will be highly valuable to Inari as we enter the next phase of our mission to treat and transform the lives of patients suffering from venous and other diseases,” said Bill Hoffman, Inari’s Chief Executive Officer.

From August 2015 to February 2018, Mr. Warner served as President and General Manager of Alcon Vision Care Franchise (Alcon). Prior to that, Mr. Warner served as President, U.S. and Canada, for Alcon from January 2012 to July 2015 and as President, Canada and Latin America, for Alcon from November 2010 to January 2012. From January 2005 to October 2010, Mr. Warner served in positions of increasing responsibility for Alcon. Mr. Warner was a member of the Alcon Executive Leadership Team for over 10 years and led the Alcon transition from Nestle to Novartis majority ownership. Since August 2021, Mr. Warner has served on the board of directors of RXSight, Inc. (NASDAQ GS: RXST), a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery, where he also serves as chair of the nominating and corporate governance committee and as a member of the compensation committee. Mr. Warner currently serves on the board two private medical device companies, i-Lumen Scientific, where he is also a member of the compensation committee, and EyeYon Medical, where he also serves as Chairman. In addition, Mr. Warner is a board member of GRACE, the Grapevine Relief and Community Exchange, a nonprofit relief agency that provides vital necessities to people who are struggling with a limited income or recent emergency. Mr. Warner holds a B.S. in Chemistry from Pace University and an MBA from Rutgers University.

About Inari Medical, Inc.
Inari Medical, Inc. is a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases. Inari has developed two minimally-invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The company purpose-built its products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE: deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by the FDA and CE Mark approved for the treatment of deep vein thrombosis. The FlowTriever system is 510(k)-cleared by the FDA and CE Mark approved for the treatment of pulmonary embolism and clot in transit in the right atrium.

Investor Contact:
ICR Westwicke
Caroline Corner
Phone +1-415-202-5678
caroline.corner@westwicke.com

FAQ

Who is Robert Warner and what is his role at Inari Medical?

Robert Warner is the newly appointed independent director on Inari Medical's board and will serve on the Audit Committee.

What is the significance of Robert Warner's experience for Inari Medical?

Warner's extensive experience with Alcon and other medical companies is expected to enhance Inari's strategic direction and operational performance.

When was Robert Warner appointed to Inari Medical's board?

Robert Warner was appointed to Inari Medical's board on March 1, 2022.

What products does Inari Medical develop?

Inari Medical develops minimally-invasive devices for treating venous diseases, specifically deep vein thrombosis and pulmonary embolism.

Is Inari Medical publicly traded, and if so, what is its stock symbol?

Yes, Inari Medical is publicly traded on NASDAQ under the stock symbol NARI.